
 
 
 
 
 
 
 
 
 We claim: 
   
 1. A method of treating a subject with a Trop-2 positive cancer comprising:
 a. administering to the subject an anti-Trop-2 antibody-drug conjugate (ADC) comprising SN-38 conjugated to an anti-Trop-2 hRS7 antibody; and 
 b. administering to the subject an ABCG2 inhibitor selected from the group consisting of fumitremorgin C, Ko143, GF120918 and YHO-13351; 
 
 wherein the subject is resistant to or relapsed from therapy with a checkpoint inhibitor. 
 
     
 2. The method of  claim 1 , wherein the ABCG2 inhibitor is YHO-13351. 
 
     
 3. The method of  claim 1 , wherein the ADC is administered at a dosage of between 8 mg/kg and 10 mg/kg. 
 
     
 4. The method of  claim 1 , wherein the subject is resistant to or relapsed from therapy with irinotecan, topetecan or SN-38. 
 
     
 5. The method of  claim 1 , further comprising: (i) screening cancer cells from the subject for sensitivity to the ADC; and (ii) selecting subjects for therapy with the ADC and ABCG2 inhibitor whose cancer cells are resistant to therapy with the ADC alone. 
 
     
 6. The method of  claim 1 , wherein the cancer is selected from the group consisting of colorectal, lung, stomach, urinary bladder, renal, pancreatic, breast, ovarian, uterine, esophageal and prostatic cancer. 
 
     
 7. The method of  claim 1 , wherein the treatment results in a reduction in tumor size of at least 15%, at least 20%, at least 30%, or at least 40%. 
 
     
 8. The method of  claim 1 , wherein the cancer is selected from the group consisting of triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, metastatic small-cell lung cancer, metastatic urothelial cancer and metastatic pancreatic cancer. 
 
     
 9. The method of  claim 1 , wherein the ADC comprises 6 to 8 molecules of SN-38 conjugated to the antibody or antigen-binding fragment thereof. 
 
     
 10. The method of  claim 1 , wherein the cancer is metastatic. 
 
     
 11. The method of  claim 10 , further comprising reducing in size or eliminating the metastases. 
 
     
 12. The method of  claim 1 , wherein there is a linker between the SN-38 and the antibody. 
 
     
 13. The method of  claim 12 , wherein the linker is CL2A and the structure of the ADC is MAb-CL2A-SN-38 
 
 
 
 
   
   
 
 
 
 
     
 14. The method of  claim 13 , wherein the 10-hydroxy position of SN-38 in MAb-CL2A-SN-38 is a 10-O-ester or 10-O-carbonate derivative using a ‘COR’ moiety, wherein “CO” is carbonyl and the “R” group is selected from (i) an N,N-disubstituted aminoalkyl group “N(CH 3 ) 2 —(CH 2 ) n —” wherein n is 1-10 and wherein the terminal amino group is optionally in the form of a quaternary salt; (ii) an alkyl residue “CH 3 —(CH 2 ) n —” wherein n is 0-10; (iii) an alkoxy moiety “CH 3 —(CH 2 ) n —O—” wherein n is 0-10; (iv) an “N(CH 3 ) 2 —(CH 2 ) n —O—” wherein n is 2-10; or (v) an “R 1 O—(CH 2 —CH 2 —O) n —CH 2 —CH 2 —O—” wherein R 1  is ethyl or methyl and n is an integer with values of 0-10. 
 
     
 15. The method of  claim 1 , wherein the antibody comprises the light chain CDR sequences CDR1 (KASQDVSIAVA, SEQ ID NO: 14); CDR2 (SASYRYT, SEQ ID NO: 15); and CDR3 (QQHYITPLT, SEQ ID NO: 16) and the heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO: 17); CDR2 (WINTYTGEPTYTDDFKG, SEQ ID NO: 18) and CDR3 (GGFGSSYWYFDV, SEQ ID NO: 19). 
 
     
 16. The method of  claim 1 , further comprising administering to the subject at least one other anti-cancer therapy selected from the group consisting of surgery, external radiation, radioimmunotherapy, immunotherapy, chemotherapy, antisense therapy, interference RNA therapy, treatment with a therapeutic agent and gene therapy. 
 
     
 17. The method of  claim 16 , wherein the therapeutic agent is a drug, toxin, immunomodulator, second antibody, antigen-binding fragment of a second antibody, pro-apoptotic agent, toxin, RNase, hormone, radionuclide, anti-angiogenic agent, siRNA, RNAi, chemotherapeutic agent, cytokine, chemokine, prodrug or enzyme. 
 
     
 18. The method of  claim 17 , wherein the drug is selected from the group consisting of 5-fluorouracil, afatinib, aplidin, azaribine, anastrozole, anthracyclines, axitinib, AVL-101, AVL-291, bendamustine, bleomycin, bortezomib, bosutinib, bryostatin-1, busulfan, calicheamycin, camptothecin, carboplatin, 10-hydroxycamptothecin, carmustine, celecoxib, chlorambucil, cisplatin, Cox-2 inhibitors, irinotecan (CPT-11), SN-38, carboplatin, cladribine, camptothecans, crizotinib, cyclophosphamide, cytarabine, dacarbazine, dasatinib, dinaciclib, docetaxel, dactinomycin, daunorubicin, doxorubicin, cyano-morpholino doxorubicin, doxorubicin glucuronide, epirubicin glucuronide, erlotinib, estramustine, epipodophyllotoxin, erlotinib, entinostat, estrogen receptor binding agents, etoposide (VP16), etoposide glucuronide, etoposide phosphate, exemestane, fingolimod, floxuridine (FUdR), 3′,5′-O-dioleoyl-FudR (FUdR-dO), fludarabine, flutamide, farnesyl-protein transferase inhibitors, flavopiridol, fostamatinib, ganetespib, GDC-0834, GS-1101, gefitinib, gemcitabine, hydroxyurea, ibrutinib, idarubicin, idelalisib, ifosfamide, imatinib, L-asparaginase, lapatinib, lenolidamide, leucovorin, LFM-A13, lomustine, mechlorethamine, melphalan, mercaptopurine, 6-mercaptopurine, methotrexate, mitoxantrone, mithramycin, mitomycin, mitotane, navelbine, neratinib, nilotinib, nitrosurea, olaparib, plicomycin, procarbazine, paclitaxel, PCI-32765, pentostatin, PSI-341, raloxifene, semustine, sorafenib, streptozocin, SU11248, sunitinib, tamoxifen, temazolomide (an aqueous form of DTIC), transplatinum, thalidomide, thioguanine, thiotepa, teniposide, topotecan, uracil mustard, vatalanib, vinorelbine, vinblastine, vincristine,  vinca  alkaloids and ZD1839. 
 
     
 19. The method of  claim 17 , wherein the immunomodulator is selected from the group consisting of cytokines, lymphokines, monokines, stem cell growth factors, lymphotoxins, hematopoietic factors, colony stimulating factors (CSF), interferons (IFN), parathyroid hormone, thyroxine, insulin, proinsulin, relaxin, prorelaxin, follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), luteinizing hormone (LH), hepatic growth factor, prostaglandin, fibroblast growth factor, prolactin, placental lactogen, OB protein, transforming growth factor (TGF), TGF-α, TGF-β, insulin-like growth factor (IGF), erythropoietin, thrombopoietin, tumor necrosis factor (TNF), TNF-α, TNF-β, mullerian-inhibiting substance, mouse gonadotropin-associated peptide, inhibin, activin, vascular endothelial growth factor, integrin, interleukin (IL), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-α, interferon-β, interferon-γ, S1 factor, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18 IL-21, IL-23, IL-25, LIF, kit-ligand, FLT-3, angiostatin, thrombospondin and endostatin. 
 
     
 20. The method of  claim 1 , further comprising administering to the subject an inhibitor of ABCB1 or ABCC1. 
 
     
 21. The method of  claim 1 , further comprising administering to the subject a tyrosine kinase inhibitor. 
 
   
 
 
 
 
 
 
 
 
